Clinical features and prognosis of multiple myeloma and orbital extramedullary disease: Seven cases report and review of literature

被引：2

作者：

Hu, Wan-Li ^{[1
]}

Song, Jia-Yin ^{[1
]}

Li, Xin ^{[1
]}

Pei, Xiao-Jiao ^{[2
]}

Zhang, Jia-Jia ^{[1
]}

Shen, Man ^{[1
]}

Tang, Ran ^{[1
]}

Pan, Zhen-Yu ^{[2
]}

Huang, Zhong-Xia ^{[1
]}

机构：

[1] Capital Med Univ, Beijing Chao Yang Hosp, Multiple Myeloma Med Ctr Beijing, Dept Hematol, 5 Jingyuan Rd, Beijing 100043, Peoples R China

[2] Capital Med Univ, Beijing Chao Yang Hosp, Dept Radiol, Beijing 100043, Peoples R China

来源：

WORLD JOURNAL OF CLINICAL CASES | 2022年 / 10卷 / 33期

关键词：

Multiple myeloma; Extramedullary disease; Periorbital; Treatment; Survival; Case report; INVOLVEMENT; PLASMACYTOMA;

D O I：

10.12998/wjcc.v10.i33.12365

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BACKGROUND Multiple myeloma (MM) complicated with extramedullary disease (EMD) has a poor prognosis and is a limiting factor in the treatment of MM, and no standard treatment is recommended in international guidelines. Few studies have reported MM with periorbital EMD. CASE SUMMARY In this paper, the clinical characteristics and survival of seven patients with multiple myeloma and orbital are described and analyzed. The common ocular symptoms were blurred vision, proptosis and/or eye movement disorders, IgG type MM may be a risk factor for orbital involvement. Of them, six patients were treated with bortezomib-based regimens. The median overall survival (OS) and progression free survival for the entire cohort were 48 and 33 mo, respectively, which was much worse than the OS reported for MM patients without orbital EMD. CONCLUSION Orbital MM may have significantly shortened survival for the entire cohort, so multidisciplinary collaboration is emphasized and recommended in the diagnosis and treatment of these difficult cases.

引用

页码：12365 / 12374

页数：11

共 30 条

[1]

Adkins JW, 1997, INT OPHTHALMOL, V20, P339

[2] Extramedullary disease in multiple myeloma [J].